US FDA grants Emergency Use Authorization to new antibody combination for mild to moderate COVID-19 in patients at high risk for progressing to severe COVID-19

Approval of combination therapy of bamlanivimab and etesevimab is based on Phase 3 BLAZE-1 trial (n=1,035) that showed the combination generated a 70% reduction in hospitalisations; and none of the patients who received treatment died.

Source:

Biospace Inc.